Thermo Fisher expects the deal to be dilutive to adjusted per-share earnings by $0.06 in the first year of ownership. Excluding financing costs, it is expected to be accretive by $0.28 in that period.
Dealbreaker on MSN29d
Thermo Fisher Beefs Up in Bioprocessing With $4B Acquisition of Solventum Biz SegmentUnder deal terms announced Tuesday, Thermo Fisher will pay $4.1 billion in cash for Solventum’s Purification and Filtration, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback